Immediate Access for the Terminally Ill Act

# Immediate Access for the Terminally Ill Act (S 3648) **What the Bill Would Do** This bill would allow terminally ill patients to access experimental drugs and medical treatments that haven't yet been approved by the Food and Drug Administration (FDA). Currently, patients with terminal illnesses can apply for access to unapproved treatments through existing FDA "Right to Try" programs, but this bill appears designed to expand or streamline that access. The legislation would potentially make it easier for dying patients to obtain experimental medications without waiting for full FDA approval, giving them more treatment options when conventional medicine has exhausted possibilities. **Who It Affects and Key Details** The bill directly impacts terminally ill patients seeking experimental treatments, pharmaceutical companies developing new drugs, and the FDA.

Patients with incurable conditions would gain faster pathways to try new therapies. The specific provisions aren't detailed in the available information, but such bills typically focus on reducing bureaucratic barriers while potentially including safeguards around patient consent and data collection. This touches on the ongoing debate between expanding patient choice at the end of life versus ensuring drugs meet safety standards. **Current Status** As of now, S 3648 remains in committee and has not advanced to a floor vote in the Senate.